In one paragraphArticle in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Lauren B NicholsDepartment of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, University of California San Diego School of Medicine, La Jolla, California, USA.ORCID https://orcid.org/0009-0000-6937-0550 Sebastian G J OakesDepartment of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, University of California San Diego School of Medicine, La Jolla, California, USA.ORCID https://orcid.org/0009-0004-0613-7881 Cynthia BehlingDepartment of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, University of California San Diego School of Medicine, La Jolla, California, USA.ORCID https://orcid.org/0000-0001-7016-2636 Jeffrey B SchwimmerDepartment of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, University of California San Diego School of Medicine, La Jolla, California, USA.ORCID https://orcid.org/0000-0001-8538-2877 NASH CRN
Funding
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8MEngaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0MInstitute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4MWashington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4MAtlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8MPediatric Trials in Non-Alcoholic Steatohepatitis (NASH)U01DK061734 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2002 to 2026
$24.4MContinuation of the Non-Alcoholic Steatohepatitis Clinical Research Network (NASHU01DK061730 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI TONASCIA, JAMES A · 2002 to 2018
$23.2MSan Diego Clinical and Translational Research InstituteUL1TR000100 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2012 to 2015
$19.7MNon Alcoholic Steatohepatitis Clinical Research NetworkU01DK061732 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy · 2002 to 2026
$12.2MThe Saint Louis University Component of the NASH CRNU01DK061718 · NIDDK · SAINT LOUIS UNIVERSITY · PI BRENT A NEUSCHWANDER-TETRI · 2002 to 2026
$12.0MVEDS Year2-Continuation of the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Data Coordinating CenterU24DK061730 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI JEANNE M CLARK, David M Shade · 2019 to 2026
$11.3MPathogenesis, prognosis, and treatment of NAFLD patientsU01DK061713 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI ANNA MAE ELIZABETH DIEHL · 2002 to 2026
$10.3MIntramural Division of the National Cancer Institute (NCI)National Center for Advancing Translational Sciences (NCATS) UL1TR000004National Center for Advancing Translational Sciences (NCATS) UL1TR000006National Center for Advancing Translational Sciences (NCATS) UL1TR000077National Center for Advancing Translational Sciences (NCATS) UL1TR000100National Center for Advancing Translational Sciences (NCATS) UL1TR000150National Center for Advancing Translational Sciences (NCATS) UL1TR000423National Center for Advancing Translational Sciences (NCATS) UL1TR000448National Center for Advancing Translational Sciences (NCATS) UL1TR000454National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) U01DK061713National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) U01DK061718National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) U01DK061728National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) U01DK061730National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) U01DK061732National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) U01DK061734National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) U01DK061737National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) U01DK061738National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) U24DK061730NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR000006NCATS NIH HHS UL1 TR000077NCATS NIH HHS UL1 TR000100NCATS NIH HHS UL1 TR000150NCATS NIH HHS UL1 TR000423NCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1 TR002345NIDDK NIH HHS U01 DK061713NIDDK NIH HHS U01 DK061718NIDDK NIH HHS U01 DK061728NIDDK NIH HHS U01 DK061730NIDDK NIH HHS U01 DK061732NIDDK NIH HHS U01 DK061734NIDDK NIH HHS U01 DK061737NIDDK NIH HHS U01 DK061738NIDDK NIH HHS U24 DK061730
6 · The paper itselfAbstract
objectivesMetabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent disease in children. Vibration-controlled transient elastography (VCTE) offers a noninvasive alternative to liver biopsy, using controlled attenuation parameter (CAP) to estimate steatosis and liver stiffness measurement (LSM) for fibrosis. However, pediatric data with histological validation are limited. This prospective, multicenter study evaluated the accuracy of CAP and LSM in pediatric MASLD.
methodsChildren with histologically confirmed MASLD from the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Database 3 underwent VCTE within 6 months of liver biopsy. CAP was evaluated for correlation with steatosis grades, and LSM for correlation with fibrosis stages. The diagnostic performance of LSM in distinguishing fibrosis stages was analyzed using histological findings as the reference standard.
resultsAmong 92 children with MASLD (mean age 13 ± 3 years), CAP values were similar across steatosis grades (median 325, 310, and 323 dB/m for grades 1-3, respectively) and showed no significant correlation with histologic steatosis (p = 0.422). Median LSM values increased with fibrosis stage (6.0-8.8 kPa), but significant differences were detected only between stage 0 and stage 3 fibrosis (p = 0.037). For advanced fibrosis (stages 3-4), area under the receiver operating characteristic curve was 0.67, with sensitivity 67%, specificity 76%, positive predictive value 40%, and negative predictive value 90%.
conclusionIn this prospective, multicenter cohort, VCTE showed modest accuracy for grading steatosis or staging fibrosis in pediatric MASLD. Improved noninvasive methods are urgently needed for evaluation and monitoring in this population.
Indexed as
Elasticity Imaging TechniquesFatty LiverLiverLiver CirrhosisNon-alcoholic Fatty Liver DiseaseAdolescentChildFemaleHumansMaleProspective StudiesROC CurveSensitivity and SpecificitySeverity of Illness IndexVibrationcirrhosisdiagnostic accuracynoninvasive testobesitysteatohepatitis
Identifiers
PMID41384644
PMCPMC12964508
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390